Member Info for CrustyPete

"upfront" *missing sorry...

Well equilibrium - firstly the number is £$75 -100m not GBP. Secondly that spend will be over a number of years not, as you conveniently overlook, and will have income coming in from both Galactica and Rukwa before all of it is required. Finally, as you can freely check should be even be interested in the answer, the BoD have always been clear that much of the required investment capital will come from off take and production partners and from lending; further equity capital from shareholders will be minimised.

Sorry if the answer does not meet your one-eyed agenda but that is exactly what the BoD have stated and, frankly, they surely have a far better idea of the outcome than you do.

More of the same methinks? Bloody disappointing.

Oh look, what a bloody surprise! When ever is this seemingly never ending supply of stock going to dry up?

So what caused the drop? Trivial volumes and values to date, so maybe a large delayed SELL yet to appear? Disappointing yet again; it seems nothing can keep this sp moving in a positive direction.

That looks like dereliction of your de-ramping duties bigbeasty, since your exit to watch paint dry the scoreboard has changed a little - now 5m sells and 21m buys.... oh and look a small tick up too.

Best you get back to your day job bb.

"That makes Scancell worth 18.7p" Does it really? Or is that only after the 1bn dilution has taken place? And ignoring any changes in the COS in the intervening period methinks.

So yes perhaps 18.7p on the worst possible scenario of a 1bn share dilution and zero increase in COS.

However that is pure pedantry on my part.

An interesting summary RR. My only comment would be that as you have already summarised the current NPV without any further dilution is 36.7p and with a full 1 bn share dilution 18.7p (I am trusting your calculations RR), however the 1bn dilution will not happen in one issue but will be gradual and to counter that, dilution, the risk over time will likely reduce as further trial and developments get funded with the new capital. In addition it also assumes that the £100m in necessary funding comes through share dilution which of course it might not - it could well come from JV's and partnerships - though I fully accept that whether via JV or partnership either of those mechanisms is also likely to constitute some form of "dilution".

Quite right Gordon, if the previous market sentiment regarding Cambay valuation needed any proof that the "fairy story" about Cambay was exactly that, just hot air, they now have all the proof they ever needed with it crystalised with a pittance of a "marked to market" valuation....

The BoD could not have done a better job of shareholder value destruction of they tried. It is verging on criminal.

Yes indeed updates now coming on a regular basis. It begs the question of whether operational activity would now be progressing id it hadn't been for Selan strong arming Roland and SYN board into a fire sale...? I suspect that Selan would still be sitting on their hands waiting for SYN to wither on the vine.

Within the last hour:

https://www.linkedin.com/company/blue-star-helium-limited/posts/?feedView=all

Another milestone has been achieved for the Galactica project. Wellsite compression has been successfully delivered and installed on the first wells, coinciding with the completion of the gathering system trenching and main trunk line.

hashtag#Helium hashtag#Energy hashtag#ASX hashtag#BNL hashtag#Colorado hashtag#BlueStarHelium hashtag#HeliumOne hashtag#exploration hashtag#production hashtag#drilling hashtag#OperationsUpdate hashtag#ASX_BNL hashtag#BSNLF hashtag#GalacticaProject hashtag#CommercialProduction

Https://www.linkedin.com/company/scancell-limited/posts/

Our CEO Phil L'Huillier spoke with Karen Jagoda about iSCIB1+ ImmunoBody®, our off-the-shelf DNA immunotherapy, for the Empowered Patient Podcast.

Empowered Patient is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment.

Phil and Karen discussed what makes Scancell’s technology and platform unique and the positive Phase 2 data on iSCIB1+ in late-stage melanoma. Phil also talked about how this has accelerated development plans, including regulatory and partnering discussions, with randomised studies on the path to registration expected to begin in 2026.

As Phil says: “Our objective for patients is to pick up the patients that are unresponsive to current therapies or that respond for a short period of time to improve the overall survival through developing therapies that give a good duration of response, potent immune responses, but are also safe for patients."

Thanks to Karen for this interesting conversation, which you can listen to here https://lnkd.in/ehVFc_aR

hashtag#Cancer hashtag#Oncology hashtag#Patients hashtag#Healthcare hashtag#Melanoma hashtag#ImmunoBody hashtag#Immunotherapy

DNA Immunotherapy Shows Durable Response in Advanced Melanoma with Phil L’Huillier Scancell

empoweredpatientradio.com

Indeed wryape and not too long before someone tells us that the MM's cut the price to "close out" some stop losses at just below 1.50p....

Anyway I will be back to see what the state of play is after the close. I now have to get ready for the funeral and wake of a very old friend of mine that unfortunately died recently and relatively young.

So I wish you all well one and all.

Let's hope that they are right and it is nothing more than that....

Or maybe MM manipulation? ;0)

I'm sure those wiser than me will still be telling us all that the fall is purely caused by the "shock of the placing"?!? Lol ;0)

Quite a fall today :0(. I wonder if there is anything behind it? Though not a lot of volume, so unlikely methinks. I note also that the fall has triggered a few "bottom fishers", or maybe they know that something newsworthy is just around the corner and I would agree that there is plenty of upside here at these prices but, it feels a bit like catching a falling knife here at the moment. I will be sitting on my hands for a little while yet.....

I hope and expect that after completion of the ESP project He1 will have quite a lot of use for the Rig for their own drilling campaign Ben.....

"everything"?? Anything....?

Those delayed sales explain last week's sp fall despite the great data. But yes, violindog, same story different day; good, even great, data does nothing sustained here on the sp and a seemingly never ending supply of shares to the MM's in the background. "Commercials" and beyond just our Genmab payments, is all that will create sustained upward sp movement here....